BioSpace News Archive

Merck, known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide, an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver Annual Congress from June 21-24.

PharmaTher Holdings Ltd., a commercial-focused specialty pharmaceutical company, provides a corporate update outlining the development and commercialization plans and upcoming milestones for its KETARX™ products and PharmaPatch™ delivery system.

Genelux Corporation announced a private placement for 900,000 shares of the Company’s common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, before deducting offering expenses payable by Genelux.

HanAll Biopharma (KRX: 009420.KS) and Daewoong Pharmaceutical (KRX: 069620.KS) today announced the expansion of their open collaboration strategy by investing in Vincere Biosciences, a Cambridge, MA-based company developing therapeutics targeting mitophagy.

Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya, Co-Founder and Chief Executive Officer, Dr. Samarendra Mohanty, Co-Founder and President, and Dr. Victor Hugo Gonzalez, Valley Retina Institute, will participate in a fireside chat at Baird’s Biotech Discovery Series.

Huma Therapeutics (“Huma”), a leading global digital health company, today announced that it has received U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform.

TriSalus Life Sciences® Inc., an oncology company in the process of going public through a business combination transaction with MedTech Acquisition Corporation, announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023.

AVROBIO, Inc. announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell gene therapy program for cystinosis to Novartis for $87.5 million in cash.

Parthenon Therapeutics today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from an international panel of cancer experts convened to provide an initial consensus on the role of immune exclusion in cancer.

Simcere Pharmaceutical Group Limited announced a Sponsored Research Agreement with Mass General Brigham.